RAPID ALERT

DRAP ALERT No: I/S/9-24-31

CRACKDOWN AGAINST SPURIOUS/FALSIFIED DRUG PRODUCTS

Date: 06th September, 2024.

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public

Alert Summary:

The Directorate of Drugs Control (DDC) Punjab has detected the following falsified drug products based on their analysis from Drug Testing Laboratories (DTLs).

The details of the identified products are as under:

S#	Product Name	Composition	Batch No.	Manufactured by (as stated on the label)	Test Results
01	Ativan 2mg Tablets	Lorazepam	17C7019	Purported to be manufactured by M/s. Pfizer Pakistan, Karachi	Spurious
02	Marfix 400mg Tablet	Cefixime	MK-0002	M/s. Mirak Pharmaceutical, Lahore	Spurious
03	Payodine 10g/100ml Solution	Povidone-Iodine	002709	M/s. A.Mannan Lab, Karachi	Spurious
04	Froxime 400mg Capsule	Cefixime	FRX-400/C-6	M/s. Froxx Pharmaceuticals, Karachi	Spurious & Misbranded
05	Noa-Xime 400mg Capsule	Cefixime	nx-00525-02	M/s. Noa Hemis Pharmaceuticals, Karachi	Spurious & Misbranded
06	Biovim Injection	Benzyl Penicillin 500000 IU, Procaine Penicillin 1500000 IU	C. B-86	M/s. Uniline Pharma, Karachi	Spurious
07	Novazone Plus Drench	Oxyclonazde 3% w/v, Levamisole HCl1.5% w/v, Cobalt Sulphate 0.075% /v, Selenium Selenite 0.035%	061		Spurious

Note: The red color font in the table indicates fake products and manufacturers' names. These are not licensed or registered by DRAP.

DRAP, Islamabad **+ 92 051 9255969** **gsms@dra.gov.pk**

Risk Statement:

Falsified products are not safe to use as they may contain incorrect or harmful ingredients, leading to ineffective treatment, therapy failure, severe side effects, or adverse events.

Action initiated:

The regulatory field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection and removal of these products from the market. All pharmacists and chemists working at distributions and pharmacies should **immediately check** their stocks and **stop supplying** these products. The remaining stocks should be quarantined and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product.

Advice for Healthcare Professionals:

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by these products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link.

Further information on reporting problems to DRAP is available at this link.

Advice for Consumers / General Public:

Consumers should stop using these products and shall contact to their physician or healthcare provider(s) if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre through online or using the mobile application available at this link.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad | + 92 051 9255969 | gsms@dra.gov.pk